On brain MRI, T1 hypointensities increased within preexisting lesions.
Slowly expanding brain lesions (SELs) are multiple sclerosis (MS) demyelinating plaques with ongoing destruction at the edge. Pathological studies show that the edges of these chronically active lesions have a rim of lymphocytes, macrophages, and activated microglia. SELs have a decreasing T1 signal within existing lesions over time, suggestive of ongoing axonal injury. In this study, investigators evaluated SELs in 555 patients with primary progressive MS as part of the manufacturer-sponsored phase 3 ORATORIO clinical trial evaluating ocrelizumab versus placebo.
Within existing lesions, nonenhancing T1 hypointensity volume increased in both treatment groups. Ocrelizumab-treated patients had very few new T2 lesions, and their overall lesion …
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)